AEON Biopharma (AEON) Net Income towards Common Stockholders (2021 - 2026)

AEON Biopharma has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$37.1 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 1540.37% year-over-year to -$37.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.2 million (down 192.28% YoY) and the FY2025 annual result came in at -$39.2 million, down 193.37% from the prior year.
• Net Income towards Common Stockholders declined to -$37.1 million in Q4 2025 per AEON's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $164.1 million in Q2 2024 and troughed at -$297.7 million in Q3 2023.
• A 5-year average of -$14.9 million and a median of $18478.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 90729.6% in 2023, then soared 18608.22% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at $4.6 million in 2021, then sank by 99.6% to $18478.0 in 2022, then tumbled by 1611264.63% to -$297.7 million in 2023, then soared by 100.87% to $2.6 million in 2024, then sank by 1540.37% to -$37.1 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$37.1 million, -$4.5 million, and -$6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.